相关实验视频

Updated: Jun 9, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

诱导化疗用于局部区域先进的鼻腔状细胞癌

Arash Abiri¹, Derek H Liu¹, Theodore V Nguyen¹

¹Department of Otolaryngology-Head and Neck Surgery, University of California, Irvine, Orange, California, United States.

Journal of neurological surgery. Part B, Skull base

|October 24, 2024

概括

在手术前的诱导化疗 (IC) 显著改善了晚期鼻腔状细胞癌 (SNSCC) 的存活率. 年龄,性别,种族和瘤阶段等因素预测了IC的使用,指导了多式联络治疗策略.

科学领域:

在瘤学瘤学.
头部和部手术头部和部手术
医学瘤学医学瘤学

背景情况:

区域性先进的鼻腔状细胞癌 (SNSCC) 管理正在发展.
新出现的证据表明,诱导化疗 (IC) 在最终治疗中起着作用.
本研究评估了IC对SNSCC的生存及其利用预测因素的影响.

研究的目的:

评估诱导化疗 (IC) 对局部发达状状细胞癌 (SNSCC) 患者的整体生存期 (OS) 的影响.
确定IC在SNSCC治疗中的使用预测因子.

主要方法:

对2004-2017年国家癌症数据库对局部区域性晚期SNSCC (T4/M0) 患者的分析.
治疗的分层分为七组,包括最终化疗 (CRT),IC与CRT,IC与CRT和救援手术,最终手术 (Sx),IC与Sx,Sx与辅助疗法 (ATx) 和IC与Sx与ATx.
对于OS的Cox比例危险回归和IC预测器的物流回归.

主要成果:

总共分析了3,162名患者; 2年和5年的生存率分别为58.6%和42.0%.
与CRT相比,包括手术在内的治疗,特别是IC + Sx + ATx (HR:0.468),显著降低了死亡率.
在与绝对手术相结合时,IC提供了额外的OS益处 (p < 0.05). 预测IC的预测因素包括年龄较大,女性性别,黑人种族,T4b阶段和更高的N阶段.

结论:

在最终手术之前的诱导化疗,有或没有辅助疗法,证明了晚期SNSCC的最高整体存活率.
年龄,性别,种族和T / N阶段表现为IC利用的重要预测因素.
优先考虑手术的多模式治疗策略可能为SNSCC提供最有效的治疗反应.

关键词:

诱导化疗是一种诱导化疗.新辅助性化疗是一种新辅助性化疗.研究结果研究成果.鼻癌 (sinonasal carcinoma) 是一种癌症.幸存率幸存率生存率

更多相关视频

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...